Introduction {#Sec1}
============

Cost-of-illness (COI) studies provide information on the economic burden of a specific disease from a societal, public payer, family or individual perspective. They aim to evaluate not only the disease-related healthcare costs but also the overall costs to society, including both medical and non-medical costs. COI studies can aid the understanding of the importance of a health problem, estimate the main cost components and the cost structure, and, thus, provide valuable cost estimates for use in full economic evaluations \[[@CR1]\]. As a result, COI studies are an important type of health economic analysis aiming to support health policy and financing decision-making processes \[[@CR2]\]. Over the past decade, health technology assessment has been implemented in most Central and Eastern European (CEE) countries, which, in turn, necessitates reliable, local country-specific COI studies \[[@CR3]--[@CR5]\].

There are no gold standard methods for calculating COI estimates \[[@CR6]--[@CR8]\]. Although standardization of the methods used in COI studies is becoming more and more important to allow comparability, studies apply different designs, methodologies, perspectives, and costing approaches \[[@CR9], [@CR10]\]. Until now, several systematic reviews of COI studies have been conducted; however, most of them were focusing on one specific disease. Few reviews targeted a single specific cost item or component, such as informal care, direct medical costs, productivity loss, a specific geographic area, or a specific methodological aspect \[[@CR10]--[@CR13]\]. Nonetheless, COI studies from CEE countries have not been reviewed to date, with the exception of Austria \[[@CR13]\].

This review has been undertaken to provide a description of the COI studies in nine CEE countries, namely Austria, Bulgaria, the Czech Republic, Croatia, Hungary, Poland, Romania, Slovakia, and Slovenia, in the past 10 years. The main objectives were to describe study characteristics, methodology, and the COI estimates reported. First, we provide an overview of applied methods. Then, we present and compare the COI estimates across CE countries.

Methods {#Sec2}
=======

Search strategy {#Sec3}
---------------

We conducted a systematic review following the PRISMA statement \[[@CR14]\]. A literature search was performed using Medline, EMBASE, The Cochrane Library, CINAHL, and Web of Science databases to identify studies that report data on the cost of a disease. The search strategy was based on the keyword "cost of illness" and the name of the given CEE country (online Appendix 1). The search was limited to studies published in the past 10 years (1 January 2006---31 October 2016) and was updated on 30 June 2017 to shorten the time between the end of the search period and publication date. No language restrictions were applied. A complementary, non-systematic literature search was conducted in three countries. Three authors (SM, KT, and ZB) hand-searched for further papers in selected, peer-reviewed, non-indexed local journals in Austria, Bulgaria, and Hungary. The review protocol was not registered.

Study selection {#Sec4}
---------------

After removing duplicates, titles and abstracts of studies were reviewed independently by ZB, VB, and LG, and were retrieved if at least one of the reviewers considered the study to be relevant. First, abstracts (publication type) and reviews (publication type) were excluded. Full-text papers of the remaining studies were reviewed and included (ZB, VB, and LG). Any disagreement between reviewers was solved by discussions among the authors to reach consensus.

Studies were selected for further analysis if they met the following inclusion criteria: (i) COI data included for a specific disease without major restriction on the patient population, e.g., by age, co-morbidity, complication, or treatment, (ii) full-text paper, (iii) original research, and (iv) the study population was recruited in Austria, Bulgaria, the Czech Republic, Croatia, Hungary, Poland, Romania, Slovakia, or Slovenia. Studies were not selected for further analysis if they represented clinical trials, reviews, cost-effectiveness studies, budget impact analyses, treatment-related (drug) studies, costs of health programs (e.g., screening), or studies enrolling a patient population with co-morbidities (e.g., diabetic patient with depression).

Data extraction {#Sec5}
---------------

A Microsoft Excel spreadsheet was developed to extract data from the identified studies, including general characteristics of the study (year of publication, geographical location, language, and funding source), methodological details of the study (disease, data collection method, study design, setting, costing year, currency, and perspective and costing methods), and results (direct costs, indirect costs, and total costs in euros). The list of extracted variables was created based on health economic checklists and adjusted by screening of six (10%) random articles \[[@CR6], [@CR15]\]. Costs reported in currencies other than euro were converted to euro at a mean annual exchange rate, and all costs were inflated to 2017 prices using the harmonised consumer price index extracted from Eurostat \[[@CR16]\]. To facilitate cross-country comparisons, costs were also described as a percentage of 2017 GDP per capita. Diseases were categorised according to the International Statistical Classification of Diseases and Related Health Problems 10th Revision (ICD-10 Version:16) \[[@CR17]\]. Data extraction was conducted by ZB and respective authors for national languages and double-checked.

Results {#Sec6}
=======

Study selection {#Sec7}
---------------

As can be seen from Fig. S1 (online Appendix), after removing 246 duplicates, the search in the electronic databases resulted in 607 potentially relevant papers. Of these studies, 55 were not full-text papers and 98 were reviews. Furthermore, 282 papers did not report disease-related costs, 54 focused on costs of multiple diseases, and 67 focused on the cost of a certain treatment. Overall, 50 articles from the electronic search fulfilled the inclusion criteria. The supplementary local search resulted in another eight relevant articles in non-indexed, peer-reviewed journals (Austria: *n* = 2, Bulgaria: *n* = 5, and Hungary: *n* = 1).

Altogether, we included 58 articles (involving also multi-country studies) that reported results for Hungary (*n* = 24), Bulgaria (*n* = 16), Poland (*n* = 11), Czech Republic (*n* = 10), Austria (*n* = 9), Slovenia (*n* = 4), Croatia (*n* = 3), Slovakia (*n* = 3), and Romania (*n* = 3).

Thirteen additional COI studies did not meet to our eligibility criteria (e.g., involved samples restricted by age, co-morbidity, complication, or treatment), but we found their results worthy of attention, and hence, a summary of their characteristics and main results is presented in online Appendix 1.

Study characteristics {#Sec8}
---------------------

The majority of publications reported costs from one country (74%), but 15 studies presented results from multiple countries, and hence, altogether, 83 country-specific results were provided by 58 studies (Table [1](#Tab1){ref-type="table"}). Three-quarters of the studies were published in English (*n* = 44), and except for five papers \[[@CR18]--[@CR22]\], all non-English papers had an English abstract. Most of the publications (n = 45, 78%) presented costs in euro. In 37 studies, the national currency was converted to euro; of them, 17 (46%) studies stated explicitly exchange rate, 5 (14%) studies reported only the source of exchange rate, and 15 (40%) studies did not mention conversion at all. Among countries outside the euro zone, reporting costs in national currency was most common in Romania (67%). Overall, 47 (81%) studies stated the source of funding. The lack of a funding statement was most prevalent in Romania (*n* = 2, 67%) and in Bulgaria (*n* = 5; 31%). Only two studies received funds from two different sources, both of them were funded by the European Union (EU) and the local government. Regarding clinical areas, endocrine, nutritional, and metabolic diseases were the most common, in which costs were analysed (*n* = 15 country-specific results), followed by neoplasms (*n* = 12), and certain infectious and parasitic diseases (*n* = 10) (Fig. [1](#Fig1){ref-type="fig"}). Altogether 48 different diseases were analysed in the 58 included articles.Table 1Characteristics of cost-of-illness studiesCharacteristicNumber of country-specific results:*N* = 83; Number of papers:*N * = 58^1^Total^a^Austria \[[@CR24], [@CR33], [@CR58]--[@CR64]\]Bulgaria \[[@CR18]--[@CR22], [@CR27]--[@CR29], [@CR32], [@CR59], [@CR65]--[@CR70]\]Croatia \[[@CR27], [@CR59], [@CR71]\]Czech Republic \[[@CR23], [@CR27], [@CR34], [@CR36], [@CR59], [@CR72]--[@CR76]\]Hungary \[[@CR26]--[@CR30], [@CR35], [@CR41], [@CR59], [@CR65], [@CR67], [@CR68], [@CR75]--[@CR86]\]Poland \[[@CR25], [@CR27], [@CR59], [@CR75], [@CR76], [@CR87]--[@CR92]\]Romania \[[@CR37], [@CR59], [@CR93]\]Slovakia \[[@CR59], [@CR75], [@CR76]\]Slovenia \[[@CR27], [@CR31], [@CR59], [@CR94]\]Total number of studies916310241133458 English511310211113444 National language45003020014Search Electronic database search711310231133350 Hand-search25NANA1NANANANA8Currency Euro910310211013345 National currencyNA6003120113Source of resource use data Retrospective cross-sectional, self-completed questionnaire690315100028 Retrospective chart review1102210105 Interview-based prospective cohort1201031008 Retrospective claims data0001531108 Combination of various sources^b^1212121136 Modelling0121110012 NR0100000001Perspective Public payer22222301210 Societal280318400130 Patient2000000002 Hospital0500001006 NR51154422113Costing method Top--down11011201012 Bottom--up3101316201222 NR55267731224Indirect cost calculation method Human capital580318701134 Friction cost11121111111 NR0000200002 N/A37252321211Informal care monetary valuation Proxy good08101610005 Opportunity cost1103211113 NR20020100020 Other1000000001 N/A57256722329Funding source EU18009100013 Pharmaceutical industry52138413111 Government10053100013 Other0001000001 None21214300211 NR15000320111Cost per patient reported Direct medical costs5131420531138 Indirect costs6102621912338 Informal care cost491518311129 Total costs8133723933347Any unit costs Reported381716521224 NR68238612234*NR* not reported, *N/A* not applicable^a^Several studies published results for multiple countries. These studies are referred in each relevant country columns in a row, while, in the total column, a study might be referred only once in a row. Therefore, adding numbers in a row results in a larger sum than in the total column^b^Studies used combination of various sources of data: peer-reviewed published studies, national reports from governmental or professional bodies, extrapolations from similar countries, aggregated macrolevel data, claim data, and questionnaire surveyFig. 1Distribution of COI studies by ICD classification. **a** Distribution of country-specific results across clinical areas defined by ICD groups (*n* = 83). **b** Distribution of studies between clinical areas defined by ICD groups (*n* = 58)

Methods {#Sec9}
=======

Analyses by countries are presented in Table [1](#Tab1){ref-type="table"}. The most frequently used data source was a retrospective, self-completed resource use questionnaire (48%), followed by retrospective claims data analysis (14%) and prospective diary (14%). Sample sizes ranged from *n* = 2 (small cohorts) to *n* = 127,512 (large population-based study). Of the 58 studies included in the review, 26 (45%) presented aggregated results for each main cost category (i.e., direct medical, direct non-medical, and indirect). The majority of studies applied the societal perspective (52%), followed by the public payer perspective (17%). If reported, bottom--up (38%) and top--down (21%) methods were used for estimating the costs in the studies. Productivity losses were estimated in 47 (81%) studies; of them, the human capital approach and friction cost method were used in 34 (72%) and 11 (23%) studies, respectively, and the method was not specified in 11 (23%) studies. Studies that reported costs of informal care (*n* = 29) applied the proxy-good method (17%) or the opportunity cost method (10%), but the name of the applied method was not stated in most of them (69%). Unit costs were not reported at all in 58% of the studies.

Cost-of-illness: comparison across countries in one disease {#Sec10}
-----------------------------------------------------------

Eighty-three COI estimates were reported for 48 different diseases. Apart from rare diseases, multiple sclerosis caused the highest economic burden in terms of average total annual cost per patient in three countries (Austria €50,599, the Czech Republic €14,777, and Poland €12,343) \[[@CR23]--[@CR25]\]. In Hungary, schizophrenia (€15,187), and in Bulgaria, gestational diabetes (€32,263) were the most costly diseases \[[@CR22], [@CR26]\].

Multi-country studies were conducted in nine diagnoses (rotavirus gastroenteritis, pneumonia, bladder cancer, hypoglycaemia, Duchenne muscular dystrophy, epidermolysis bullosa, Prader--Willi syndrome, cystic fibrosis, and haemophilia). One multi-country study (bladder cancer) was conducted in nine countries and another (hypoglycaemia) in six countries. Two studies were conducted (rotavirus gastroenteritis and pneumonia) in four countries and four studies (Duchenne muscular dystrophy, epidermolysis bullosa, Prader--Willi, and haemophilia) in two countries. The bladder cancer study involving nine countries resulted in mean total costs of €7421; however, costs differed significantly among countries, as the total cost was between €2320 (Bulgaria) and €16,479 (Slovenia). The direct medical cost ranged between €1090 (Bulgaria) and €8050 (Slovenia), and indirect cost varied between €912 (Bulgaria) and €6398 (Slovenia). The hypoglycaemia study was conducted in six countries, and the total overall societal cost per patient with diabetes was €11 and ranged between €5 (Bulgaria) and €18 (Slovenia) \[[@CR27]\]. Rotavirus gastroenteritis and pneumonia studies were conducted in four countries and the average total costs were €541 and €764, respectively. Costs varied between €494 (Czech Republic) and €747 (Poland) in rotavirus gastroenteritis, and between €472 and €1111 in pneumonia. Duchenne muscular dystrophy, epidermolysis bullosa, Prader--Willi syndrome, cystic fibrosis, and haemophilia were studied in two countries (Hungary and Bulgaria) applying the same methodology in a European Commission founded rare disease study (BURQOL-RD project). Prader--Willi syndrome was the least costly (Bulgaria: €3842 Hungary: €12,532) and mucopolysaccharidosis was the most costly rare disease (Bulgaria: €77,414; Hungary: €25,326) \[[@CR28], [@CR29]\].

Unique studies in more than one country were conducted in eight diagnoses, namely multiple sclerosis, dementia, Parkinson's disease, rheumatoid arthritis, osteoporosis, chronic obstructive pulmonary disease (COPD), systemic sclerosis, and diabetes. Multiple sclerosis and diabetes were studied most often (four studies each), while three unique studies in three different countries were conducted in Parkinson's disease and two unique studies in three different countries were conducted in cystic fibrosis. Two unique studies on both dementia and COPD were conducted in two different countries. In multiple sclerosis, there was a 4.1 times difference in total costs between Austria (€50,599) and Poland (€12,343) \[[@CR24], [@CR30]\]. In diabetes, the highest direct cost was observed in Hungary (€1309) and the lowest total cost was observed in Bulgaria (€472) \[[@CR31], [@CR32]\]. In Parkinson's disease, there was a 3.3 times difference in total costs between Austria (€22,984) and the Czech Republic (€6970) \[[@CR33], [@CR34]\]. In dementia, we found a 3.5 times difference in total costs between the Czech Republic (€2013) and Hungary (€671) \[[@CR35], [@CR36]\]. The costs of COPD were similar in Bulgaria (€1839) and Romania (€2103) \[[@CR21], [@CR37]\].

Adjusting costs for GDP per capita level, differences between countries decreased (Table [2](#Tab2){ref-type="table"}). For instance, a 7.1-fold difference in bladder cancer and a 4.1-fold difference in multiple sclerosis were reduced to 2.4- and 1.5-fold, respectively. Comparing diseases with available cost estimates from more than one country (Fig. [2](#Fig2){ref-type="fig"}), a positive relationship was identified between costs and GDP per capita.Table 2Cost-of-illness in nine CEE countries (€ 2017)DiseaseCountryStudyCosting yearSample sizePerspectiveResource use data sourceEUR/patient/year converted to € 2017Total cost as % of GDP/capitaTotal costsDirect medicalDirect non-medicalIndirect costsI. Certain infectious and parasitic diseases (ICD A00--B99) Acute gastrointestinal infectionsPOLCzech et al. \[[@CR87]\]2009NRSocietalInterview-based prospective cohort, follow-up period = 4 weeks19677161031.7% Clostridium difficile infectionHUNKopcsóné Németh et al. \[[@CR95]\]^a^2011151HospitalRetrospective chart review656--1397NRNRNR5.2--11.1% HIV infectionAUTGrabmeier-Pfistershammer et al. \[[@CR58]\]200624NRRetrospective chart review28,572NRNRNR5.7% Rotavirus gastroenteritisCZEHUNPOLSVKTichopad et al. \[[@CR75]\]2013109NR112115PayerRetrospective chart review494324747597NRNRNRNRNRNRNRNRNRNRNRNR2.7%2.6%6.2%3.8%II. Neoplasms (C00--D48) Bladder cancerAUTBULHRVCZEHUNPOLROUSVKSVNLeal et al. \[[@CR59]\]2012NRNRPublicly available sources and claims data were combined12,988232060357266454567573812867716,479796510902520451127483466175061438050NR3292912272519351061233315481749639830.9%32.7%51.1%40.1%36.1%55.8%39.7%55.6%78.5% Breast cancerHUNInotai et al. \[[@CR41]\]2012127,512NRRetrospective claims data1622NRNRNR12.9% Cervical cancerPOLDubas-Jakóbczyk et al. \[[@CR88]\]2012NRSocietalPublicly available sources and social insurance data were combinedNRNRNR8457,898^f^NA Colorectal cancerHUNInotai et al. \[[@CR41]\]2012118,235NRRetrospective claims data2010NRNRNR16.0% Lung cancerHUNInotai et al. \[[@CR41]\]2012126,731NRRetrospective claims data2663NRNRNR21.1% Prostate cancerHUNInotai et al. \[[@CR41]\]Brodszky et al. \[[@CR40]\]2012200556,38217,642PayerPayerRetrospective claims dataRetrospective follow-up cohort of claims data, follow-up = 8 years165612,072NRNRNRNRNRNR13.1%95.8% Skin melanomaHRVBencina et al. \[[@CR71]\]2011NRPayerModellingStage 0: 104--stage 4: 4610NRNRNR1.0-39.1%VI. Diseases of the nervous system (G00--G99) Alzheimer's diseaseCZEMaresova et al. \[[@CR73]\]2014NRNRPublicly available sources and claims data were combinedNR13,208NR73.0% DementiaHUNCZEÉrsek et al. \[[@CR35]\].Holmerová et al. \[[@CR36]\]2008201488119SocietalNRCross-sectional self-completed questionnaireCross-sectional self-completed questionnaire6712013^b^222387631769^b^5.3%11.1%238^b^ EpilepsyHUNPéntek et al. \[[@CR83]\]2009100SocietalCross-sectional self-completed questionnaire2650885465130021% Multiple sclerosisAUTCZEHUNPOLKobelt et al. \[[@CR24]\]Dusankova et al. \[[@CR23]\]Péntek et al. \[[@CR30]\]Szmurlo et al. \[[@CR25]\]2005200720092012101990968NRSocietalSocietalSocietalSocietalCross-sectional self-completed questionnaireProspective cohort, follow-up = 3 msCross-sectional self-completed questionnaireExtrapolation from other country50,59914,77713,11512,34321,78875818744580510,109550157651018,399664626966028120.5%81.6%104.1%102.0% Parkinson's diseaseAUTCZEHUNCampenhausen et al. \[[@CR33]\]Winter et al. \[[@CR34]\]Tamás et al. \[[@CR85]\]20082004200981100110SocietalSocietalSocietalCross-sectional self-completed questionnaireCross-sectional self-completed questionnaireCross-sectional self-completed questionnaire22,9846970725713,833423891512733253430.9%38.5%57.6%25862136IX. Diseases of the circulatory system (I00--I99) Acute myocardial infarctionHUNGulácsi et al. \[[@CR80]\].2003996SocietalClaims dataNRNRNR9477.5% Chronic heart failurePOLCzech et al. \[[@CR92]\]2010400Public payerInterview-based prospective cohort, follow-up period = 4 weeks1991NRNRNR16.5% Coronary artery diseasePOLJaworski et al. \[[@CR89]\]20052593NRCross-sectional self-completed questionnaire28511365NR148623.6% Subarachnoide bleedingBULGeorgieva et al. \[[@CR18]\]^a^201461HospitalProspective cohortNR3685NRNR51.9%X. Diseases of the respiratory system (J00--J99) Bronchial AsthmaBULIvanova et al. \[[@CR20]\]^a^2014112Hospital costRetrospective chart review200--393^c^200--393^c^NRNR2.8-5.5% COPDBULROUKyuchukov et al. \[[@CR21]\]^a^Stâmbu et al. \[[@CR37]\]NR20068485Hospital and patientNRProspective cohortInterview data183921038982103NRNRNRNR25.9%21.9% Lower respiratory tract infectionBULGlogovska et al. \[[@CR19]\]^a^NR1441 ambulatory + 353 hospitalizedHealth systemNRNR1218NRNR17.2% PneumoniaCZEHUNPOLSVKTichopad et al. \[[@CR76]\]2010258NR198315NRClaims dataAges 50--64/\> 651194/7861009/686714/4721685/1111Ages 50--64/age \> 65708/786686/686472/4721190/1111Ages:50-64/\> 65486/0323/0242/0495/06.6%/4.3%8.0%/5.4%5.9%/3.9%10.8%/7.1% *Streptococcus pneumoniae*ROUStoicescu et al. \[[@CR93]\]200448,200Public payerClaims data8.3 million8.3 millionNRNRNAXIII. Diseases of the musculoskeletal system and connective tissue (M00.0--M99.9) Chronic non-specific back painAUTWagner et al. \[[@CR64]\]^a^200848Public payerRetrospective self-completed questionnaire21481687461NR5.1% OsteoporosisSVNAUTDzajkovska et al. \[[@CR94]\]Dimai et al. \[[@CR62]\]20032008NR441/population-basedSocietalNRPublicly available sources and claims data were combinedPublicly available sources and retrospective self-completed questionnaire were combined34,524,727^d^827,849,562^d^24,432,069^d^520,419,423^d^110,092,657^d^307,430,139^d^NANA Osteoarthritis of hip and kneeAUTWagner et al. \[[@CR63]\]2008174Public payerRetrospective self-completed questionnaire321113421869NR7.6% Rheumatoid arthritisCZEHUNKlimes et al. \[[@CR72]\]Péntek et al. \[[@CR86]\]20142004261255SocietalNRCross-sectional self-completed questionnaireCross-sectional self-completed questionnaire9176553674421733303450.7%43.9%1524978 Systemic lupus erythematosusPOLKawalec et al. \[[@CR90]\]20121600NRClaims dataNRNRNR136311.2% Systemic sclerosisPOLHUNHUNKawalec et al. \[[@CR90]\]Lopez Basida et al. \[[@CR28]\]Minier et al. \[[@CR82]\]2012201220065003880NRSocietalSocietalClaims dataCross-sectional self-completed questionnaireCross-sectional self-completed questionnaireNR482213,769NR12724724NR1184133033942366771628.0%38.3%109.3%IV. Endocrine, nutritional and metabolic diseases (E00--E90) DiabetesBULPOLHUNSVNValov et al. \[[@CR32]\]Lesniowska et al. \[[@CR91]\]Brodszky et al. \[[@CR78]\]Nerat et al. \[[@CR31]\]2011200920032011433NR480NRPayerSocietalNRPayerRetrospective and prospective cohort, follow-up = 6 msClaims dataCross-sectional self-completed questionnairePublicly available sources4726592514NRNR2871309882NR1521118NR6.6%5.4%20.0%4.2% HypoglycaemiaHUNBULHRVCZEPOLSVNJakubczyk et al. \[[@CR27]\]2013201420122011NR2011NRPublic payer/societalModelling9.85.47.510.911.317.77.24.76.79.29.515.22.60.70.81.71.82.50.1%0.1%0.1%0.1%0.1%0.1%Other top level ICD items including \< 2 disease Benign prostatic hyperplasiaHUNRencz et al. \[[@CR84]\]2014246SocietalCross-sectional self-completed questionnaire9024172752107.2% EndometriosisAUTPrast et al. \[[@CR60]\]200973Healthcare systemCross-sectional self-completed questionnaire89456501244321.3% Gastro-oesophageal reflux diseaseAUTWillich et al. \[[@CR61]\]20005273NRProspective cohort, follow-up = 4 yrs527471551.3% Gestational diabetesBULTodorova et al. \[[@CR22]\]2002-2005195Healthcare systemCross-sectional self-completed questionnaire32,26332,263NRNR454% PsoriasisHUNBalogh et al. \[[@CR77]\]2013200SocietalCross-sectional self-completed questionnaire95247816152129275.6% Psoriatic arthritisHUNBrodszky et al. \[[@CR78]\]2007183SocietalCross-sectional self-completed questionnaire739524891053385358.7% SarcoidosisPOLKawalec et al. \[[@CR90]\]20122700NRClaims dataNRNRNR11149.2% SchizophreniaHUNPéntek et al. \[[@CR26]\]200978SocietalCross-sectional self-completed questionnaire15,187433481910,034120.5%Rare diseases Cystic fibrosisBULCZEHUNBULIskrov et al. \[[@CR70]\]Mlcoch et al. \[[@CR74]\]Chevreul et al. \[[@CR68]\]Chevreul et al. \[[@CR68]\]20122010201220123333011033SocietalNRSocietalSocietalCross-sectional self-completed questionnaireRetrospective registry analysisCross-sectional self-completed questionnaireCross-sectional self-completed questionnaire23,570^b^16,11822,12121,75918,551^b^16,11820,39321,1760^b^NR38021068332.0%89.0%175.6%306.5% Duchenne muscular dystrophyHUNBULCavazza et al. \[[@CR67]\]20125714SocietalCross-sectional self-completed questionnaire15,952650015,094228971242111450126.6%91.5% Epidermolysis bullosaBULHUNAngelis et al. \[[@CR96]\]201286SocietalCross-sectional self-completed questionnaire17,24610,262350343813,48598232590242.9%81.4% Fragile X syndromeHUNChevreul et al. \[[@CR79]\]201212SocietalCross-sectional self-completed questionnaire51801165065051.6% HaemophiliaBULHUNCavazza et al. \[[@CR66]\]20122058SocietalCross-sectional self-completed questionnaire650015,952228915,0942326158014591.5%126.6% HistiocytosisBULIskrov et al. \[[@CR69]\]20127SocietalCross-sectional self-completed questionnaire666816572865214593.9% MucopolysaccharidosisBULHUNPéntek et al. \[[@CR29]\]2012210SocietalCross-sectional self-completed questionnaire77,41425,32646,22969931,18519,862050911090.3%201.0% Prader--Willi syndromeBULHUNLopez Basida et al. \[[@CR28]\]201285SocietalCross-sectional self-completed questionnaire384212,5322489325135412,2070054.1%99.5%^a^Study identified through hand-search of local, non-indexed journals^b^Median^c^Bronchial asthma + exacerbations, bronchial asthma + pneumonia, and bronchial asthma + bronhiectasia^d^Aggregated costs for the total population of patientsFig. 2Total costs (euro 2017) and GDP per capita (2017): comparison of single-country and multi-country studies. **a** Single-country studies: each line represents one disease, and each dot represents one study and one country. **b** Multi-country studies: each line represents one study and one disease, and each dot represents one country

Discussion {#Sec11}
==========

A systematic search was conducted to provide a review of the COI studies in nine CEE countries. The diffusion of the new technologies to the health scare systems is enormous, prices, and technologies, and professional guidelines are changing; therefore, our search was limited for the past 10 years. The included papers covered a broad range of clinical areas and showed notable cross-country differences in terms of methodology and publication standards as well as the average yearly costs per patient.

Study characteristics and methodology {#Sec12}
-------------------------------------

Reporting cost results in euros was dominant over national currencies, suggesting that researchers in the CEE region find it important to make their results available for the international scientific community and allow for comparability with other studies. To assess study quality, we selected some quality indicators, such as those are used in health economics checklists. Reporting study perspective, reference year, costing method (top--down vs. bottom--up), source of resource use, valuation of informal care, valuation of productivity loss, and funding source were considered as quality indicators. We find it noteworthy to mention that whilst the source of data on resource utilization and reference year of costing were stated in nearly every paper (98% and 95%, respectively), other important quality indicators were less often reported. The study perspective was reported in 78%, the approach to valuing indirect costs in 77%, costing method in 64%, at least one unit cost in 42%, and method for valuing informal care in 31% of the studies. A recent review of economic evaluations in Austria found that the study perspective and reference year were not reported by 60% and 25% of the studies, respectively \[[@CR13]\]. Differences may be explained by inclusion of non-peer-reviewed or grey literature (e.g., economic evaluation reports from national health technology assessment agencies) and of other forms of economic evaluations in the study by Mayer et al. The review by Mayer et al. included 93 (partial and full) economic evaluations, 14 of which were cost-of-illness analyses. Out of the 93 included studies, 23 were not indexed according to the Journal Citation Reports (Social) Sciences Edition and 12 were non-peer-reviewed reports \[[@CR13]\].

Clinical areas {#Sec13}
--------------

A large variety of diseases was covered by the studies, and most of them occurred in a one study. Each disease was studied by, on average, 1.3 papers. Considering country-specific results by ICD categories, endocrine, nutritional, and metabolic diseases (18%), neoplasms (14%), infectious (12%), neurologic (11%), and musculoskeletal diseases (11%) represented the five main fields of COI research in CEE. It is difficult to judge the drivers of the selection of clinical fields. The public health importance of a disease might be an important factor as, for instance, all the studies in the 'Endocrine, nutritional and metabolic diseases' ICD category were related to diabetes, and among neoplasms studies, the most prevalent malignancies (breast, colorectal, lung, and prostate cancer) were present (Table [2](#Tab2){ref-type="table"}). According to the Global Burden of Disease study, the leading three causes of total Disability-Adjusted Life Years (DALY) included ischaemic heart disease, cerebrovascular disease, and lower respiratory infection, comprising 16% of all DALYs \[[@CR38]\]. Leading causes of DALYs were represented only in six (10%) studies (cerebrovascular disease: *n* = 1, ischaemic heart disease: *n* = 2, and lower respiratory infection: *n* = 3) in our review, questioning public health importance as a driver of topic selection in COI studies. The need for COI data to support decision-making on reimbursement of highly effective but costly new drugs seems to be another relevant issue, and this hypothesis is supported by the relatively high rate of studies in inflammatory rheumatic diseases, where biological drugs were introduced in the CEE countries in the observed period. Multiple sclerosis is another disorder where biologicals revolutionized the treatment that partly explains the relatively high rate of neurological studies in the region. Moreover, when counting papers, neurologic diseases were most frequently studied (19%). A possible explanation could be that neurologic conditions in the CEE region were priorities for state-funded or EU-funded research. Eight out of the ten COI studies focusing on neurologic diseases received funding from the local governments or EU organisations. It is interesting that neurologic diseases were found also the most frequently studied clinical area according to a recently published systematic review of EQ-5D studies in the CEE region \[[@CR39]\]. These results suggest that neurologic diseases have a high priority in health economics research in the CEE.

Comparison of costs across countries {#Sec14}
------------------------------------

With respect to diseases for which cost estimates were present in multiple countries, costs varied substantially across countries. However, there are apparent differences in the level of comparability between studies. There were multi-country studies following a standardized methodology in which more than one CEE country together with Western European countries was participated. We also identified single-country studies in various diseases using very different methods. Both multi-country and single-country studies reported significant cost differences in diseases across countries.

For the interpretation of data, it is important to take into consideration that the number of patients, sample characteristics (e.g., age, gender, disease duration, and disease severity), and the availability of costly treatments at the time of the study (e.g., biological drugs for inflammatory diseases) varied a great deal across studies that may strongly influence the COI results and their comparability. Large differences in unit costs can also cause significant variations in costs. In bladder cancer, for example, the cost of an inpatient day was seven times higher in Austria (€495) than in Romania (€67). Methodological differences, such as prevalence- and incidence-based costing, form an obstacle for the comparison of costs. Therefore, the incidence-based prostate cancer study by Brodszky et al. cannot be compared with the prevalence-based prostate cancer study by Inotai et al., although both studies were conducted in Hungary \[[@CR40], [@CR41]\]. It should also be noted that differences in health care systems (private/public, financing, etc.) might have a significant impact on costs; for instance, global budget, fee-for-service or DRG financing mechanisms, the presence of co-payments, minor or major share of private services, and many more aspects might influence the actual costs, access to health care, and, finally, the COI figure \[[@CR42]\].

According to the literature, one might expect a higher COI in a country with a higher GDP \[[@CR43]--[@CR45]\]. In many diseases (multiple sclerosis, bladder cancer, Parkinson's disease, rheumatoid arthritis, Prader--Willi syndrome, haemophilia, diabetes, and hypoglycaemia), there was a clear positive association between total costs and GDP per capita. As opposed to this, cost estimates, sometimes, inversely correlated with the per capita GDP. For instance, GDP per capita in Bulgaria is almost half of that in Hungary; nevertheless, costs of mucopolysaccharidosis were threefold higher in Bulgaria. Thus, in some cases, adjusting costs for the GDP further increased the inter-country differences. On the other hand, the 3.5-fold higher GDP per capita in Austria decreased the cross-country differences (from 4- to 1.3-fold) in costs of multiple sclerosis. In spite of the considerable heterogeneity observed in the studies included in this review, some trends could be identified. The magnitude of costs increased with the level of per capita GDP. In other words, cross-country differences decreased or even vanished when the costs were adjusted. In contrast, higher costs with lower GDP per capita could be observed only in some rare diseases (cystic fibrosis, epidermolysis bullosa, and mucopolysaccharidosis) and rotavirus gastroenteritis. Moreover, methodological differences did not seem to affect this relationship. Comparing multi-country studies in a disease applied the same methodology for more than one country and single-country studies analysed costs in the same disease, the relationship between cost-of-illness and GDP per capita showed similar pattern in these two groups of studies (see Fig. [2](#Fig2){ref-type="fig"}).

Quality, publication standards, and the assessment of transferability {#Sec15}
---------------------------------------------------------------------

Cost-of-illness studies varied considerably both in methods and in cost estimates, and serve many purposes. Methodological deficiencies, such as the lack of reporting either on the three distinct phases of costing (identifying the relevant cost items, measuring the use of the identified resources, and placing a value on these cost items) \[[@CR46]\], or other important characteristics such as the perspective of the study, related to the production function (direct and indirect costs) were the leading causes of shortcomings in comparability. However, no specific costing guidelines for health care interventions are available in these countries, and except in Austria, there is no national cost database available, providing some kind of unit cost data in a collected form \[[@CR13], [@CR47], [@CR48]\]. Another important difficulty in costing relates to the different Managed Entry Agreements (MEA), such as price volume agreements, discounts, outcome guarantees, and many more, in the reimbursement of the health technologies in the different countries \[[@CR49], [@CR50]\]. Due to the MEAs, for instance, the real purchasing price of the medicinal products is not publicly available.

Several papers were published about transferability in the past 2 decades \[[@CR51]--[@CR56]\]. At the moment, health economics and health technology assessment guidelines in CEE countries either include very limited advice or provide no guidance on the transferability or adaptation of clinical and economic data from other jurisdictions. Thus, establishing better guidelines for COI studies on transferability would be valuable for robust decision-making in the CEE countries \[[@CR56]\]. As Gao et al. stated, confirming the transferability of COI estimates across jurisdictions would contribute significantly to resolving the issue of transferability of cost-effectiveness results \[[@CR45]\]. Transferability is a very important issue around the world and especially in Central or Eastern Europe with limited resources to provide COI studies \[[@CR53]--[@CR55]\]. Data transferability and transferability of the results are not discussed in these COI studies. Both should be improved using Drummond's check list for evaluating economic evaluations \[[@CR57]\]. Transferability might be an important alternative to conduct local COIs. However, due to the methodological, data, and publication heterogeneity, the usefulness of the COI results in other jurisdictions is limited.

Limitations {#Sec16}
-----------

There are a few limitations to note. A systematic approach was taken to identify studies that have considered the costs of diseases; however, the possibility that relevant studies were not identified and included in this systematic literature review remains. Some COI results might have been missed due to excluding grey literature (i.e., conference abstracts and project reports) from our search. Other limitationis that the local search in non-indexed journals was conducted only in three of the nine countries. On the other hand, no language restriction was applied in the systematic search. Adopting a Medical Subject Heading (MeSH)-based search strategy may have led to missing some studies using keywords improperly. At the same time, the PubMed search engine uses a broad range of entry terms which may minimize the number of excluded studies. Further limitation is that no comprehensive checklist was applied, because, according to our best knowledge, there is no COI study-specific checklist in English. This might bias our conclusions on study quality, but we believe that the presented study characteristics could give a good overall description of the included studies.

Conclusions {#Sec17}
===========

Fifty-eight COI studies were identified between 1 January 2006 and 30 June 2017 published in Austria, Bulgaria, the Czech Republic, Croatia, Hungary, Poland, Romania, Slovakia, and Slovenia, providing 83 country-specific COI results. Endocrine, nutritional, and metabolic diseases, neoplasms, infectious disease, and neurological disorders were the most frequently studied clinical areas. Transferability might be an important alternative to conduct local COIs. However, due to the methodological, data, and publication heterogeneity of these 58 COI studies, the transferability is limited across the nine Central and Eastern European Countries.
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